Key result
TricValve system shows early symptom relief in ~75% of severe TR patients despite poor survival.
Why the study?
Caval valve implantation with the TricValve system is proposed for symptom reduction in tricuspid regurgitation, but early registry experience required evaluation.
Does TricValve system implantation improve symptoms and survival in high-risk patients with severe tricuspid regurgitation ineligible for T-TEER and surgery?
Observational (n=4)
Does TricValve system implantation improve symptoms and survival in high-risk patients with severe tricuspid regurgitation ineligible for T-TEER and surgery?
TricValve implantation offers short-term symptom reduction in high-risk patients with severe tricuspid regurgitation, but 1-year mortality remains high due to comorbidities and heart failure progression.
No takes yet. Share an insight, caveat, or question.
Small cohort with high mortality precludes practice change; leaves open need for larger trials of TricValve in severe TR.
Rdzanek et al. (2025) conducted an observational in Severe Tricuspid Regurgitation (n=4). TricValve system implantation was evaluated on Symptom reduction at 6 months. TricValve system implantation reduced symptoms at 6 months in 3 of 4 patients with severe tricuspid regurgitation, though only 1 patient survived to 12 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: